KEYTRUDA + Chemo Significantly Improved OS vs chemo Alone as First-Line Treatment for Advanced Malignant Pleural Mesothelioma March 15, 2023
ACE-Breast-02 Pivotal Ph 3 Study of ARX788 for the Treatment of HER2 Positive Metastatic Breast Cancer Achieves Positive Results March 15, 2023
FAILED TRIAL: Ph 3 CONTACT-03 study of cabozantinib + atezolizumab versus cabozantinib alone in RCC patients did not meet primary endpoint of PFS March 15, 2023
Enhertu Showed Clinically Meaningful and Durable Responses Across Multiple HER2-Expressing Tumour Types in DESTINY-PanTumor02 Ph 2 Trial March 15, 2023
Updated survival data from Ph 2 trial of Bria-IMT™ + retifanlimab combo in advanced metastatic breast cancer patients announced February 28, 2023
Positive Full Data Results From the Pivotal Ph 3 SIERRA Trial in Patients with Active, R/R AML announced February 28, 2023
ESMO 2023: Ad hoc interim OS study results of ZEJULA® (niraparib) from the NORA Ph 3 study and a post hoc analysis from the Ph 3 PRIME trial of niraparib maintenance therapy to be presented February 28, 2023
Encouraging early efficacy data from ModiFY Ph 1/2 trial announced: Modi-1 monotherapy showed PR and SD in SCCHN, ovarian, or TNBC patients February 22, 2023
Positive Final OS Results of Ph 3 JUPITER-02 Trial of Toripalimab as Treatment for Recurrent or mNPC announced February 22, 2023
Trodelvy® Demonstrates Positive Efficacy Treating Both Platinum-Ineligible And Rapidly Progressing, Post-Platinum Metastatic Urothelial Cancer February 22, 2023
THIO + Atezolizumab or Pembrolizumab demonstrated Significantly Greater Tumor Inhibition February 22, 2023
Final Topline Data from Successful European Ph 1 monotherapy Trial of Annamycin in R/R AML patients announced February 22, 2023
New Analyses Reinforce Survival Benefit of BAVENCIO First-Line Maintenance Treatment in Patients With Advanced Urothelial Carcinoma February 22, 2023
Opdivo® + CABOMETYX® shows Durable Survival with Over Three Years of Follow-Up in the CheckMate -9ER Trial in 1L Advanced RCC February 22, 2023
Updated Data Demonstrating Improved Outcomes from Niraparib + Abiraterone + Prednisone in 1L BRCA+ve metastatic CRPC announced February 22, 2023
Positive TALZENNA® and XTANDI® Combination Data from Ph 3 TALAPRO-2 Study Announced February 22, 2023
Adjuvant Opdivo Continues to Provide Significant, Durable Clinical Benefits for Patients with Radically Resected, High-Risk MIBC After 3 Yrs in CheckMate -274 Trial February 22, 2023
Final Results of Key Secondary OS Endpoint From Phase 3 PROpel Trial presented, OS endpoint not met February 22, 2023
KEYTRUDA + Chemo Significantly Improved OS vs chemo Alone in With HER2-Neg Gastric or GEJ Adenocarcinoma Patients Regardless of PD-L1 Expression February 22, 2023
Clinical Responses from the Ph 2 OATH Clinical Trial Evaluating ONA-XR for the Treatment of Endometrial Cancer highlighted February 22, 2023
Abecma (idecabtagene vicleucel) Reduced the Risk of Disease Progression or Death by 51% vs SoC in Earlier Lines of Therapy for R/R Multiple Myeloma in Ph 3 KarMMa-3 Study February 22, 2023
